Foundation Medicine Inc (FMI.OQ)
72.00USD
20 Apr 2018
$-0.75 (-1.03%)
$72.75
$72.40
$73.20
$72.00
26,008
110,427
$87.05
$31.70
About
Overall
| Beta: | -0.09 |
| Market Cap(Mil.): | $1,689.42 |
| Shares Outstanding(Mil.): | 36.02 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
BRIEF-Foundation Medicine - Co, Guardant Health Announced Agreement To Settle False Advertising Challenges
* FOUNDATION MEDICINE - CO, GUARDANT HEALTH ANNOUNCED AGREEMENT TO SETTLE FALSE ADVERTISING CHALLENGES THAT COMPANIES HAD FILED AGAINST EACH OTHER Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)
BRIEF-Foundation Medicine Reports Qtrly loss Per Share $1.05
* FOUNDATION MEDICINE ANNOUNCES 2017 FOURTH QUARTER AND YEAR-END RESULTS, RECENT HIGHLIGHTS AND 2018 OUTLOOK
BRIEF-Foundation Medicine Enters Into Amended And Restated Ex-US Commercialization Agreement With F. Hoffmann-La Roche Ltd
* FOUNDATION MEDICINE SAYS ON FEB 28, CO ENTERED INTO AMENDED AND RESTATED EX-US COMMERCIALIZATION AGREEMENT WITH F. HOFFMANN-LA ROCHE LTD - SEC FILING
BRIEF-Foundation Medicine, Pfizer Announce Partnership To Develop Companion Diagnostics For Pfizer’S Oncology Portfolio
* FOUNDATION MEDICINE AND PFIZER ANNOUNCE BROAD PARTNERSHIP TO DEVELOP COMPANION DIAGNOSTICS FOR PFIZER’S ONCOLOGY PORTFOLIO
BRIEF-Foundation Medicine Reports Preliminary 2017 Results
* - PRELIMINARY 2017 TOTAL REVENUE OF APPROXIMATELY $152.9 MILLION, A 31% YEAR OVER YEAR INCREASE
BRIEF-Foundation Medicine Files For Potential Mixed Shelf, Size Not Disclosed
* FOUNDATION MEDICINE INC FILES FOR POTENTIAL MIXED SHELF, SIZE NOT DISCLOSED - SEC FILING Source text: (http://bit.ly/2BO42UB) Further company coverage:
Foundation's cancer gene test gets U.S. FDA and Medicare nod
CHICAGO A test from Foundation Medicine Inc that can detect cancer-causing mutations in 324 genes has won approval from the U.S. Food and Drug Administration and the Center for Medicare and Medicaid Services, the agencies said.
UPDATE 1-Foundation's cancer gene test gets U.S. FDA and Medicare nod
CHICAGO, Nov 30 A test from Foundation Medicine Inc that can detect cancer-causing mutations in 324 genes has won approval from the U.S. Food and Drug Administration and the Center for Medicare and Medicaid Services, the agencies said.
Foundation Medicine gets nod from FDA and Medicare for cancer test
CHICAGO, Nov 30 A test from Foundation Medicine Inc that can detect cancer-causing mutations in 324 genes has won simultaneous approval from the U.S. Food and Drug Administration and the Center for Medicare and Medicaid Services, the agencies said in a statement on Thursday.
BRIEF-Foundation Medicine Q3 loss per share $0.90
* Foundation Medicine announces 2017 third quarter results and recent highlights
Competitors
| Price | Chg | |
|---|---|---|
| Roche Holding Ltd. (ROG.S) | CHF215.65 | -0.85 |
| Roche Holding Ltd. (RO.S) | CHF220.00 | -0.20 |
| Abbott Laboratories (ABT.N) | $59.10 | -0.78 |
| Quest Diagnostics Inc (DGX.N) | $98.33 | -3.16 |
| Laboratory Corp. of America Holdings (LH.N) | $164.88 | -3.38 |
| Qiagen NV (QGEN.N) | $32.70 | -0.09 |
| Bio-Reference Laboratories Inc (BRLI.OQ) | -- | -- |
| Myriad Genetics, Inc. (MYGN.OQ) | $28.98 | -0.06 |
| Genomic Health, Inc. (GHDX.OQ) | $32.20 | 0.00 |
| Sequenom, Inc. (SQNM.OQ) | -- | -- |
Estimates